跳至主要内容
临床试验/NCT07799168
NCT07799168尚未招募不适用

Dengue Evaluation of Multi-State Models (DENEM Study): A Prospective Observational Study of Patients Hospitalised With Dengue Vascular Leak in Nha Trang, Vietnam, to Develop Novel Statistical Methodology

Liverpool School of Tropical Medicine1 个研究点 分布在 1 个国家目标入组 235 人开始时间: 2026年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
235
试验地点
1
主要终点
Degree of vascular leak

研究概览

简要总结

The goal of this observational study is to investigate the natural history of dengue in hospitalised patients in Vietnam, to better understand the disease process, and utilise the data to improve future clinical trials. The main questions it aims to answer are:

In participants hospitalised with dengue in Vietnam:

  1. How does dengue illness change over time, particularly the development and recovery of vascular leak (where blood vessels leak)?
  2. Can a new statistical approaches describe dengue illness accurately and be suitable for use in future clinical trials?
  3. Which blood biomarkers are associated with worsening or improving dengue illness, and what do they tell us about how severe dengue develops? Could these blood biomarkers act as reliable indicators of disease severity and recovery, making them useful outcome measures in future dengue treatment trials?
  4. How accurately do simplified diagnostic tests identify dengue compared with laboratory reference methods, and are they suitable for use in research and clinical settings in low- and middle-income countries?

Participants will be observed without any intervention throughout their hospitalisation. Participants will be be asked to provide informed consent for:

  • Recording of their routine clinical data
  • Regular blood tests
  • Regular ultrasound scans
  • A follow up appointment.

详细描述

Dengue is a life-threatening infection caused by a virus, spread between humans by the bite of mosquitoes. It is present throughout the tropics, including in Vietnam, where cases have dramatically increased in recent years. Dengue causes severe illness predominantly through vascular leak, where patients' blood vessels break down, becoming leaky, leading to fluid from the vessels moving into tissues and organs such as the lungs.

However, it is still not fully understand how the virus causes vascular leak, or in which patients it is most likely to occur in. There are no licensed treatments for vascular leak. This is because the mechanism of vascular leak is incompletely understood, making therapeutic targeting difficult. Additionally, when drugs are trialled, many trials have been poorly designed and not included enough patients.

To answer our research questions, the investigators will recruit 142 patients admitted to hospital with dengue in Nha Trang, Vietnam who have dengue vascular leak. If they are happy to enter the study, data will be recorded that is already being collected as part of their hospital admission; this will include clinical data (such as blood pressure, pulse and treatments given) and the results of their blood tests. Investigators will also run tests beyond what they would normally have in hospital; this will include the results of regular ultrasound scans and biomarker blood tests (small molecules that can be detected in their blood in response to stress and vascular leak). Most patients have blood tests daily in hospital, and clinicians will aim to take the extra tubes of blood required at the same time, to minimise the number of extra procedures requested from participants.

Investigators will put this data it into a statistical model of dengue vascular leak they have been developing, called a multi-state model. These models have previously been used in other areas of medicine, but this would be their first application in dengue and infectious diseases research. Multi-state models aim to track how patients move through different stages of illness over time. Models such as this make better use of all the information collected during a patient's illness. Rather than only looking at a single outcome, such as whether a patient had recovered by a certain day, or how long recovery took, they track how patients move through different stages of dengue over time and how long they spend in each stage. This may give a more complete picture of how treatments affect the course of illness. If successful, it could improve how future dengue clinical trials are designed, helping researchers detect whether new treatments work more quickly and with fewer volunteers.

Investigators will also use data and samples collected from this study to explore why vascular leak occurs and evaluate new ways of diagnosing dengue, particularly in low-resource settings. To achieve this, investigators will need to compare patients who have dengue to people who have not got dengue, looking for differences. As such 93 people who do not have dengue (called "control" participants) will be recruited. Some will have a fever from another cause, and others will be healthy volunteers. Comparing these control populations with patients who have dengue helps us understand which findings are specific to dengue and how accurate new dengue tests are. People in these groups will only have a single small blood sample taken and will not receive any treatment or need follow-up visits.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • (hospitalised cohort):
  • Meet the 2009 WHO criteria for dengue with warning signs or severe dengue AND
  • Are being admitted as an inpatient AND
  • Have documented standard-of-care laboratory confirmation of dengue (defined as either positive by molecular assay (e.g. reverse transcription polymerase chain reaction) OR positive by antigen testing (non-structural protein-1) OR positive Immunoglobulin M (IgM) combined with clinical diagnosis of dengue by attending physician. AND
  • Were born in Vietnam (only for platelet phenomics substudy)
  • Inclusion Criteria (diagnostic control cohort):
  • Have a documented fever at assessment AND
  • Have a documented negative standard-of-care dengue test, with no clinical diagnosis of dengue AND
  • Were born in Vietnam (only for platelet phenomics substudy)
  • Inclusion Criteria (platelet control cohort):
  • Vietnamese-born adults ≥16 years of age with no history of febrile illness in the preceding 14 days.

排除标准

  • Receiving an experimental dengue treatment during their illness.
  • Inability to provide written, informed consent AND no legal guardian able to provide written, informed consent in the event of incapacity.
  • Clinician-determined unsuitability for recruitment.
  • Exclusion Criteria (platelet substudy only):
  • Any non-steroidal anti-inflammatory, antiplatelet or anticoagulant medication received in preceding 7 days.

研究组 & 干预措施

Hospitalised Cohort

Patients hospitalised with dengue with warning signs or severe dengue

Diagnostic Control Cohort

Patients with non-dengue febrile illness

Platelet Control Cohort

Healthy Vietnamese volunteers

结局指标

主要结局

Degree of vascular leak

时间窗: From enrollment until day 10 of illness, or discharge

Presence and severity of vascular leak (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - composite of change of haematocrit from baseline, presence of ascites/pleural effusion by point of care ultrasound and presence of respiratory/cardiovascular compromise.

次要结局

  • Viral dynamics(From enrollment until day 10 of illness, or discharge)
  • Multi-state model evaluation: model fit(From enrollment until day 10 of illness or discharge)
  • Multi-state model evaluation - precision(Assessed at 3 days and 5 days post admission)
  • Degree of thrombocytopenia(From enrollment until day 10 of illness or discharge)
  • Degree of bleeding(From enrollment until day 10 of illness or discharge)
  • Modified sequenetial organ failure score (mSOFA)(From enrollment until day 10 of illness or discharge)
  • Volume of Intravenous Fluid Received in 24 hours(From enrollment until day 10 of illness or discharge)
  • Dengue Clinical Severity(From enrollment until day 10 of illness or discharge)
  • Concentration of a panel of plasma biomarkers of endothelial dysfunction, inflammation and platelet dysfunction.(From enrollment until day 10 of illness, or discharge)
  • Performance of plasma biomarkers of dengue vascular leak as robust secondary endpoints in future dengue interventional trials.(From enrollment until day 10 of illness or discharge)
  • Performance of dengue diagnostic platforms, for use in participant screening in low- and middle-income countries.(At enrollment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验